The efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm
Amna Zafar(Massachusetts General Hospital), Tomas G. Neilan(Albert Einstein College of Medicine), Maeve Jones‐O’Connor(Harvard University), Carlos A. Gongora(Harvard University), Hannah Gilman(Massachusetts General Hospital), Colin D. Weekes(Massachusetts General Hospital), Uvette Lou(Harvard University), Thiago Quinaglia(Cardiovascular Research Center), Matthew Lei(Massachusetts General Hospital), Sean Murphy(Massachusetts General Hospital), Zsófia D. Drobni(Semmelweis University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Ali Mahmood(Morristown Medical Center), John R. Clark(Harvard University), Erica Tavares(University of California, San Francisco), Ryan David Nipp(Harvard University), Sarah Hartmann(Massachusetts General Hospital), Ramya Mosarla(Harvard University)
Cited by 27
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k